Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 25Recruiting 18Active not recruiting 12Withdrawn 5Terminated 4Unknown 3Not yet recruiting 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 1

Conditions

Leukemia, Myeloid, Acute 4Prostatic Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Breast Neoplasms 3Advanced Solid Tumor 3Pancreatic Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Hypoxia 2Advanced Solid Tumors 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Pelvic Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Mesothelioma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Monocytic, Acute 1Leukemia, Biphenotypic, Acute 1

Interventions

Cytarabine 85Cyclophosphamide 58Azacitidine 57fludarabine 52venetoclax 41fludarabine phosphate 41Busulfan 30Filgrastim 23Whole-Body Irradiation 22Decitabine 21Mycophenolic Acid 20Methotrexate 19Mitoxantrone 18Etoposide 18Antilymphocyte Serum 18Cyclosporine 17Clofarabine 17Tacrolimus 16Granulocyte Colony-Stimulating Factor 16Peripheral Blood Stem Cell Transplantation 15Daunorubicin 15Melphalan 13thymoglobulin 11Thiotepa 11Stem Cell Transplantation 11Interleukin-2 11Idarubicin 10Gemtuzumab 9Cord Blood Stem Cell Transplantation 9aldesleukin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Leukemia, Myeloid, Acute × Injections × Clear all
NCT03404193 2026-03-10

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 2 Terminated
235 enrolled
MyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04526288 2024-05-23

CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease

Fred Hutchinson Cancer Center

Phase 2 Terminated
1 enrolled 6 charts
Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

NCT03904251 2023-11-18

CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Jonsson Comprehensive Cancer Center

Phase 1 Terminated
13 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT03146871 2019-04-18

Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent

University of Southern California

Phase 2 Terminated
7 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡